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Background and Aims: Despite the negative results of blocking IL-17 in Crohn’s
disease (CD) patients, selective modulation of Th17-dependent responses warrants
further study. Inhibition of retinoic acid-related orphan receptor gamma (RORγt), the
master regulator of the Th17 signature, is currently being explored in inflammatory
diseases. Our aim was to determine the effect of a novel oral RORγt antagonist (BI119)
in human CD and on an experimental model of intestinal inflammation.
Methods: 51CD patients and 11 healthy subjects were included. The effects of
BI119 were tested on microbial-stimulated peripheral blood mononuclear cells (PBMCs),
intestinal crypts and biopsies from CD patients. The ability of BI119 to prevent colitis
in vivo was assessed in the CD4+CD45RBhigh T cell transfer model.
Results: In bacterial antigen-stimulated PBMCs from CD patients, BI119 inhibits
Th17-related genes and proteins, while upregulating Treg and preserving Th1 and
Th2 signatures. Intestinal crypts cultured with supernatants from BI119-treated
commensal-specific CD4+ T cells showed decreased expression of CXCL1, CXCL8
and CCL20. BI119 significantly reduced IL17 and IL26 transcription in colonic and
ileal CD biopsies and did not affect IL22. BI119 has a more profound effect in ileal
CD with additional significant downregulation of IL23R, CSF2, CXCL1, CXCL8, and
S100A8, and upregulation of DEFA5. BI119 significantly prevented development of
clinical, macroscopic and molecular markers of colitis in the T-cell transfer model.
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Conclusions: BI119 modulated CD-relevant Th17 signatures, including downregulation
of IL23R while preserving mucosa-associated IL-22 responses, and abrogated
experimental colitis. Our results provide support to the use of RORγt antagonists as
a novel therapy to CD treatment.
Keywords: Th17, commensal antigens, T-cell-transfer, RORγt inhibition, Crohn’s disease
INTRODUCTION
Crohn’s disease (CD) is a chronic remitting and relapsing
inflammatory bowel disease (IBD) whose incidence is increasing
worldwide. While management of active disease and its
complications has dramatically improved thanks to the
introduction of biologics, the lack of response to available
therapy, intolerance and/or loss of initial response still leads to
intractable disease in a significant percentage of patients. Thus,
the quest for new therapies, especially those that can change the
natural history of the disease, continues.
Among the mechanisms involved in disease pathophysiology,
the production of IL-17 by immune cells was initially described in
animal models of intestinal inflammation and later on in patients
suffering from IBD (1–3). More recently, our group described an
exacerbated Th17 response toward bacterially derived proteins
(FlaX, A4-fla2 and YidX) in patients suffering from CD (4).
These increased bacterial responses were identified within the
peripheral CD4+ T cell compartment of CD patients compared
to controls, and were characterized by the production of larger
amounts of IL-17A and overexpression of a number of Th17
signature transcripts (i.e., IL17F, IL26, RORC, CCR6, CCL20, and
PTGER2) while showing similar expression of classical Th1 genes.
Evidence of Th17 axis involvement is also strongly supported
by the fact that IL-23 (a cytokine involved in stabilization and
further maturation of the IL-17 response) has also been critically
involved in experimental models of intestinal inflammation (5,
6). More importantly, an anti-IL23/p19 monoclonal antibody
(mAb) has shown promising efficacy in CD phase II studies (7)
and is currently undergoing further development (8).
However, blocking IL-17 in CD patients unexpectedly resulted
in negative effects (9–11), despite being efficacious in other
immune-mediated diseases (12). IL-17 blockade in CD patients
led in some cases to disease worsening, presumably due to
severe infections, including mucocutaneous candidiasis. As a
consequence, complete blockade of IL-17 using mAbs has
been excluded from the IBD-armamentarium. Nevertheless, the
contribution of IL-23 responding and potentially bacterial-driven
pathogenic IL-17 producing cells to disease activity should not
Abbreviations: AU, arbitrary units; C. albicans, Candida albicans; CDEIS, CD
endoscopic index of severity; CFSE, carboxyfluorescein succinimidyl ester; CFU,
colony-forming unit; CRP, C-reactive protein; DMSO, dimethyl sulfoxide; EAE,
autoimmune encephalomyelitis; ELISA, enzyme-linked immunosorbent assay;
FACS, fluorescence-activated cell sorting; FBS, fetal bovine serum; fdr, false
discovery rate; IL, interleukin-; ILC3, group 3 innate-like cells; LBD, ligand-
binding domain; mAb, monoclonal antibody; mLN, mesenteric lymph nodes;
PBMCs, peripheral blood mononuclear cells; PCR, Polymerase Chain Reaction;
RIN, RNA integrity number; RORγt, retinoic acid-related orphan receptor gamma;
SCID, severe combined immunodeficient.
be yet dismissed. Alternative strategies to modulate pathogenic
IL-17 responses, while preserving immune competence toward
fungi and pathogenic bacteria in the gut, need to be designed
and explored. In that sense, retinoic acid-related orphan receptor
gamma (RORγt) inhibitors offer one promising strategy. RORγt
is the master transcriptional factor that regulates the expression
of the Th17 signature both in T cells (including αβ as well as γδ T
cells abundant in the intra-epithelial compartment) and group 3
innate-like cells (ILC3) (13, 14).
Several small molecules targeting RORγt have been identified
and tested in murine cells and models. These compounds not
only suppress Th17 differentiation and IL-17 production, but also
reduce the severity of experimental autoimmune diseases (15–18)
including the IL10−/− model of colitis (19).
In view of all this, we investigate herein the impact of a
novel small molecule RORγt inhibitor (BI119) in controlling
CD-associated immune responses. Given the diversity of RORγt
expressing cells, and their varying roles and contributions
to disease in peripheral and mucosal sites, we tested the
effects of the compound both in microbial specific peripheral
CD4+ responses and in inflamed ileum and colon from CD
patients.
Finally, the effects of this novel oral compound were evaluated
in vivo using the CD4+CD45RBhigh T cell transfer colitis model.
This mouse model recapitulates the aberrant CD4+ T cell
response to commensal bacteria wherein transferred naive T cells
become activated by gut bacteria in SCID recipient mice and
mount a strong immune response resulting in similar pathology
to that found in CD (20).
MATERIALS AND METHODS
Additional information is provided in Supplementary Methods.
Study Subjects
Patients diagnosed with CD (n = 51) by endoscopic, histological
and radiological criteria were recruited for the study for blood
or biopsy collection. Healthy subjects (n = 6) without any
known underlying acute or chronic pathological condition served
as control blood donors. Epithelial crypts were obtained from
surgical resection specimens from non-IBD individuals (n = 5)
undergoing surgery for colorectal cancer; a segment of healthy
mucosa was collected at least 10 cm from the margin of the
affected area. Supplementary Tables S1, S2 show the clinical
and demographic characteristics from non-IBD subjects and
CD patients. This study was carried out in accordance with
the recommendations of ethics committees at the Hospital
Clínic de Barcelona, Hospital Mutua de Terrassa and Hospital
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Universitari de Bellvitge-IDIBELLwith written informed consent
from all subjects. All subjects gave written informed consent
in accordance with the Declaration of Helsinki. The protocol
was approved by ethics committees at the Hospital Clínic de
Barcelona, Hospital Mutua de Terrassa and Hospital Universitari
de Bellvitge-IDIBELL.
Compound Description
The RORγt inhibitor BI119 (Boehringer Ingelheim
Pharmaceuticals Inc., Ridgefield, CT, USA) was discovered
by screening a small-molecule compound library. BI119 strongly
bound to the human RORγ ligand-binding domain (LBD)
and was active in an RORγ LBD reporter assay (Kd for RORγ
LBD– 65 nM; IC50 for RORγ LBD reporter assay 260 nM).
The compound showed high selectivity toward RORγt as
demonstrated by a lack of significant activity against RORα
(IC50> 10µM) and RORβ (IC50> than 6µM).
Antigen Stimulation of Human PBMCs
Peripheral blood mononuclear cells (PBMCs) were isolated from
heparinized peripheral blood by Ficoll (Sigma-Aldrich, Madrid,
Spain) gradient centrifugation. Cells were cultured in X-VIVO 15
medium (BioWhittaker, Lonza, Belgium) supplemented with 2%
inactivated AB human serum (Sigma-Aldrich) for 7 days. PBMCs
were cultured with the microbial commensal proteins FrvX
(Prometheus Laboratories Inc., San Diego, CA, USA) and YidX
(exonBio, San Diego, CA, USA) at 2µg/ml. An unstimulated
condition was used as negative control. Heat-killed Candida
albicans (C. albicans) was kindly provided by the Microbiology
Department, Hospital Clínic-IDIBAPS, Barcelona, Spain and was
used at 1 colony-forming unit (CFU): 1 PBMC as a positive
control for IL-17 producing T cells. Recombinant interleukin
(IL)-2 (20 UI/ml) (R&D systems, Minneapolis, MN, USA) was
added to the culture on day 3. For RORγt blocking experiments,
PBMCs were cultured in the presence of BI119 at 1µM or
dimethyl sulfoxide (DMSO) (vehicle control, 1:10,000). On the
seventh day, supernatants were centrifuged and stored at −20◦C
until assayed. PBMCs were washed with cold PBS, re-suspended
in 600 µL of buffer RLT (Qiagen, Hilden, Germany) and stored
at−80◦C until RNA extraction.
Human Intestinal Crypt Isolation and
Culture
Non-IBD intestinal epithelial crypts were isolated from intestinal
tissue as previously described (21). For short-term crypt culture,
40 isolated crypts/25 µl Matrigel (BD Biosciences) were plated
and cultured in either complete crypt culture medium or in
medium containing supernatants from activated sorted antigen-
specific CD4+ T cells (more detailed information is provided
in Supplementary Materials and Methods). Antigen-specific T-
cell supernatants were obtained from re-stimulating sorted cells
with corresponding antigen (FrvX or YidX) treated with or
without BI119. After overnight culture of crypts, RNA was
extracted.
Culture of Human Biopsies
Intestinal biopsies (4–6 per patient) were obtained from inflamed
areas (defined by the presence of ulcers) of the colon or ileum
from CD patients. Biopsies were washed twice in RPMI 1640
medium (Lonza, MD, USA) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (Biosera, France), 100 U/ml
penicillin, 100 U/ml streptomycin and 250 ng/ml amphotericin B
(Lonza), 10µg/ml gentamicin sulfate (Lonza) and 1.5mMHepes
(Lonza). Whole biopsies were divided in two wells and cultured
in the presence of BI119 at 1µM or vehicle control (DMSO,
1:10,000) at 37◦C in humidified atmosphere containing 5% CO2
incubator for 18 h. Total RNA was isolated and transcriptional
analysis was performed.
RNA Isolation From Human Samples
Total RNA was isolated using RNeasy mini kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions. Purity
and integrity of the total RNA were assessed using the 2100
Bioanalyzer (Agilent, Germany) and quantified with a NanoDrop
spectrophotometer (Nanodrop Technologies, DE, USA). Only
samples with an RNA integrity number (RIN) greater than 7.0
were used.
Quantitative Real-Time Polymerase Chain
Reaction (qPCR)
Total RNA (250 ng) was transcribed to complementary DNA
using a reverse transcriptase (High Capacity cDNA Archive RT
kit, Thermo Fisher Scientific, Waltham, MA, USA). Quantitative
real-time PCR (qPCR) was performed in an ABI PRISM 7500
Fast RT-PCR System (Applied Biosystems) using predesigned
TaqMan Assays (Applied Biosystems). ACTB was used as a
reference gene and arbitrary units (AU) were calculated relative
to ACTB.
CD4+CD45RBHigh T Cell Transfer Colitis
Model
This study was carried out in accordance with the
recommendations of Boehringer Ingelheim’s Institutional
Animal Care and Use Committee.
CB6F1 female mice served as cell donors and female CB.17
severe-combined immunodeficient (SCID) mice as recipients
(Jackson Labs, Sacramento, CA). Mice were allowed a minimum
of 2 weeks for acclimatization in specific pathogen-free
conditions with 12-h light/dark cycle. All mice were used at 8–10
weeks of age with access to food and water provided ad libitum.
CB6F1 mice were humanely sacrificed and spleens collected
on ice. Following homogenization of spleens and red blood
cells lysis, CD4+ cells were enriched from pooled spleen cells
using a commercially available negative selection kit (Stemcell
Technologies, Vancouver, BC) following the manufacturer’s
protocol. CD4+ enriched cells were stained with Alexa Flour 488
conjugated anti-CD4 clone RM4-5, Alexa Flour 647 conjugated
anti-CD45RB clone C363-16A and PE conjugated anti-CD25
clone PC61 (Thermo Fisher Scientific). CD4+CD45RBhigh cells
were sorted on a FACSAria II (BDBiocsience). CD4+CD45RBlow
cells were collected separately. Groups of recipient CB.17 SCID
mice were injected intraperitoneally with (5 × 105) purified
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CD4+CD45RBhigh donor lymphocytes in 200µL PBS. A separate
group of recipients was injected with the same quantity of non-
colitogenic CD4+CD45RBlow lymphocytes as a control. A group
of CB.17 SCID normal mice was also used as a control. All mice
were weighed and observed weekly for clinical signs of illness
including piloerection, hunched posture, decreased skin turgor
and eye crusting. Diseased animals were humanely sacrificed
for analysis at 4 weeks post-transfer or when body weight loss
exceeded 20% of starting weight.
Compound Dosing on Mice
BI119 was suspended in MC/tween solution (0.5%
methylcellulose, 0.015% polysorbate 80) using a dounce
homogenizer until a uniform suspension was formed. Recipient
mice that received CD4+CD45RBhigh cells were administered
either MC/tween or 100 mg/kg BI119 by oral gavage immediately
prior to cell transfer and then twice daily until study termination.
Data Analysis
Statistical analysis was performed using Bioconductor tools
in R (V. 3.4.2). In experiments performed with human
samples, differences between continuous variables were tested
with nonparametric test (unpaired or paired Mann-Whitney-
Wilcoxon test). Error bars show the mean and standard error
of the mean (SEM). P-values were adjusted by false discovery
rate (fdr) and were considered statistically significant when
equal or less than 0.05. Regarding mice experiments, significance
testing was performed by one-way ANOVA and Sidak’s multiple
comparisons test. For the total sum histopathology score, the
Kruskal Wallis test and Dunn’s multiple comparison test was
performed.
RESULTS
Expression of TH17-related Genes Is
Reduced by BI119
In order to evaluate the efficacy of a small molecule antagonist
for RORγt, we stimulated human PBMCs to secrete measurable
amounts of IL-17 in response tomicrobial antigens. Here we used
the fungi C.albicans as a positive control because it is a strong
inducer of Th17 responses. In addition, we used two different
Escherichia coli-derived proteins: FrvX, which was selected based
on reported increased sera reactivity in CD (22), and YidX,
which we previously showed as capable of inducing exacerbated
Th17 responses in CD patients (4). Supplementary Figure 1
shows production of IL-17, IFNγ, and IL-5 by stimulated PBMCs
from both non-IBD donors (n = 6) and CD patients (n = 6)
(Supplementary Table 1, Patient group 1). YidX and FrvX
induced the production of significantly higher concentrations of
IL-17, but not Th1 and Th2-related cytokines, in CD patients
compared to non-IBD controls. In contrast, as expected, C.
albicans induced similar increases in IL-17 levels in controls and
CD patients compared to unstimulated conditions.
Using this system, we next tested the effect of a specific
RORγt inhibitor (BI119) on the expression of a number of gene
transcripts and proteins. PBMCs from an independent group of
CD patients (n = 12; Supplementary Table 1, Patient group 2)
were cultured alone or stimulated with C.albicans, FrvX, and
YidX in the presence of BI119 (1µM) or vehicle control. BI119
significantly reduced transcription of the Th17-related genes
RORC, IL17A, IL17F, IL22, IL26, and IL23R under all conditions
studied, while it did not alter RORA expression (Figure 1A
and Supplementary Figure 2A). IL-17A (Figure 1A) and IL-22
(Supplementary Figure 2B) protein concentrations in culture
supernatants from stimulated PBMCs were also significantly
reduced by BI119 compared to vehicle-treated conditions.
Remarkably, the Th1 or Th2 master regulators (TBX21 and
GATA3 respectively), or their main effector cytokines (IFN-
γ and IL-5), were not regulated by BI119 under any of the
conditions studied (Figures 1B,C). In contrast, BI119 induced a
small but significant (paired analysis, adjusted p< 0.05) increase
in both FOXP3 transcription and IL-10 production in microbial-
stimulated PBMCs from CD patients (Figure 1D). These data
demonstrate that BI119 strongly and specifically blocks Th17-
related genes induced by microbial stimulation of CD PBMCs,
though it does not interfere with Th1 and Th2 responses and
up-regulates a Treg expression profile.
BI119 Reduces the Pro-Inflammatory
Effects of Commensal Antigen-Specific
CD4+ T Cells on Healthy Human Crypts
It has been described that IL-17 acts on epithelial cells by
enhancing the expression of neutrophil and Th17 recruiting
chemokines such as CXCL1, CXCL8 and CCL20, while it
represses the Th1-attracting cytokine CXCL10 (4). Here we tested
whether treating microbial activated CD4+ T cells with BI119
could reduce their inflammatory effect on the epithelial layer. We
focused only on FrvX and YidX because their relevant responses
in CD patients (4).
In order to do this, CFSE-labeled PBMCs from CD patients
(Supplementary Table 1, Patient group 3) were stimulated with
FrvX (n = 8) or Yidx (n = 7). Responding CFSE−CD4+ T
cells were sorted and re-stimulated with their cognate antigen
in the presence of BI119 or vehicle control (Figure 2A). After
7 days supernatants from these cultures were collected and
added to whole colonic crypts from non-IBD surgical specimens
(n = 5). Supernatants from both FrvX and YidX-specific
CD4+ T cells induced a marked up-regulation of CXCL1,
CXCL8, CCL20, and CXCL10 transcription on intestinal crypts
(Figures 2B–E). Remarkably, supernatants from FrvX and YidX-
specific CD4+ T cells treated with BI119 showed a significantly
lower induction of CXCL1, CXCL8, and CCL20 by intestinal
crypts (Figures 2B–D). In contrast, CXCL10 expression was
either increased or unchanged under the same conditions
(Figure 2E). Our results collectively indicate that the specific
inhibition of RORγt on T cells modulates their pro-inflammatory
effects on the epithelial lining.
Effect of RORγt Inhibition on Inflamed
Intestinal Mucosa From Crohn’s Disease
Patients
Thus far we have shown that BI119 effectively inhibits
RORγt-dependent gene transcription and protein secretion on
Frontiers in Immunology | www.frontiersin.org 4 October 2018 | Volume 9 | Article 2307
Bassolas-Molina et al. RORγt Inhibition in CD
FIGURE 1 | BI119 selectively inhibits Th17-related genes in PBMCs from CD patients. (A) Th17, (B) Th1, (C) Th2, and (D) Treg-related gene and protein expression
were determined on PBMCs from CD patients (n = 12) after 7 days of culture in the presence of microbial antigens. Messenger RNA expression of transcription
factors was assessed by real-time polymerase chain reaction. Protein production was measured by ELISA on PBMCs supernatants. Mean ± SEM. ns > 0.05,
*P ≤ 0.05, **P < 0.005, ***P < 0.0005.
circulating PBMCs responding to microbial antigen stimulation,
specifically on CD4+ T cells. Expression of RORγt, however, is
not limited to these lymphocyte populations. Indeed, intestinal
mucosa cell types poorly represented in peripheral blood (i.e.,
intraepithelial lymphocytes and ILC3 cells) have been shown to
express the Th17 transcriptional regulator.
Therefore, we investigated the effect of RORγt inhibition
in intestinal tissue explants (endoscopic biopsies) obtained
from the inflamed involved mucosa of CD patients (n = 18;
Supplementary Table 2, Patient group 4) to assess the effect
of BI119 on direct as well as indirect targets in tissue. Based
on the differential cellular composition and transcriptional
profiles between colonic and ileal mucosa, we analyzed separately
the effects of RORγt inhibition on both intestinal locations.
Samples were taken from inflamed colonic (n = 10) and
ileal (n = 8) CD segments with comparable endoscopic
disease severity based on their segmental CD endoscopic index
of severity (CDEIS) score (Supplementary Table 2). Despite
comparable disease severity, we found higher basal expression
of IL17A and S100A8 in ileal samples compared to colonic ones
(Supplementary Figure 3). In contrast, expression of other genes
regulated in inflammation as CXCL1, CXCL8, IFNG, IL6 and
IL10 was comparable between colonic and ileal CD samples,
suggesting that the differences in IL17A and S100A8 expression
may potentially reflect differences in disease location rather than
degree of inflammation. The tissue specific marker DEFA5 was,
as expected, also significantly over-expressed in ileal compared to
colonic CD.
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FIGURE 2 | RORγt inhibition of activated antigen-specific CD4+ T cells reduces the expression of neutrophil-recruiting chemokines by intestinal epithelial crypts. (A)
Schematic figure of experimental plan. CFSE-labeled PBMCs were stimulated with FrvX (n = 8) or YidX (n = 7) during 12 days. Responding CFSE−CD4+ T cells were
sorted and re-stimulated with their cognate antigen and were treated or not with BI119. After 7 days supernatants were obtained from these cultures, and added to
intestinal human crypts (n = 5). After overnight culture RNA of the crypts was extracted. Messenger RNA expression of (B) CXCL1, (C) CCL20, (D) CXCL8, and (E)
CXCL10 was assessed by real-time polymerase chain reaction. Mean ± SEM. ns > 0.05, *P ≤ 0.05, **P < 0.005.
Despite these variances in basal expression, treatment with
BI119 significantly reduced transcription of IL17A, IL17F, and
IL26 in both the colon (Figure 3A) and ileum (Figure 3B) of
CD patients with active inflammation. Remarkably IL22 was
not affected in either location, in striking difference to our
results in PBMCs (Supplementary Figure 2). Other genes that
are significantly regulated in CD mucosa compared to non-IBD
controls (data not show) such as IL23R, CSF2, CXCL1, CXCL8,
IFNG, S100A8, IL6, IL10, and DEFA5 were also significantly
changed by BI119 in ileal CD, whereas the effect on colonic
biopsies did not reach statistical significance in most cases. These
results suggest that BI119 can modulate some of the Th17-related
genes, as well as inflammation-related genes, while preserving
IL22 expression in inflamed samples from active CD. Moreover,
they indicate that ileal, compared to colonic, Th17 responses may
be more amenable to modulation by RORγt antagonists.
In contrast to the experiments shown in Figure 1 using
microbial antigen-expanded CD4+ T cells from PBMCs, BI119
did not significantly regulate the expression of RORC in tissue
explants. Noticeably, the RORC gene can encode for 4 different
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FIGURE 3 | Differential expression of Th17, Th1 and CD-related genes in BI119- treated intestinal biopsies from active CD patients. Messenger RNA levels of
untreated (A) colonic (n = 8–10) and (B) ileal (n = 6–8) biopsies were set as the 100% value for each donor (dashed line), and expression of BI119–treated samples
was shown as the percentage thereof. Gray: Th17-related genes. Black: Th1-related genes. Mean ± SEM. ns > 0.05, *P ≤ 0.05.
isoforms, 2 of which give rise to the proteins RORγ and RORγt.
The fact that RORγ can be expressed by most cells in the
mucosa, including epithelial cells (data not shown), may explain
the differences in RORC modulation between PBMCs and tissue
explants. As the TaqMan assay used here does not differentiate
between the two isoforms, we cannot accurately measure
changes specifically related to RORγt using whole biopsy
tissue.
Treatment of T-Cell-Transfer Colitic Mice
With BI119 Ameliorates the Disease
Finally, the efficacy of BI119 in vivo was assessed in a
murine colitis model induced by transfer of CD4+CD45RBhigh
T cells into T- and B-cell-deficient CB.17 SCID mice. Mice
that received CD4+CD45RBhigh cells were orally administered
either MC/tween (vehicle control) (n = 11) or 100 mg/kg
BI119 (n = 12) twice a day for 28 days. Mice that were
injected with a non-colitogenic CD4+CD45RBlow population
(n = 9) and untreated CB.17 SCID mice (n = 9) were
used as controls. Transfer of CD4+CD45RBhigh T cells
into immune-depleted mice induced a significant decrease
in body weight, and a significant increase in macroscopic
(colon weight-to-length ratio), histologic, fecal (lipocalin), and
circulating (plasmatic sCD14) markers of inflammation at
day 28 compared to both control groups (Figures 4A–E).
Oral administration of BI119 significantly reduced both fecal
lipocalin and circulating sCD14 compared to vehicle treatment
(Figure 4B). A significant decrease in mucosal thickness due
to a decrease in crypt hyperplasia was also observed in mice
receiving BI119 (Figure 4C). Furthermore, administration of
BI119 significantly reversed clinical and macroscopic signs of
inflammation, while histologic improvement did not reach
statistical significance (p = 0.18 vs. vehicle group) despite a
clear amelioration on epithelial changes, mucosal inflammation
and gland loss in compound-treated mice (Figures 4D,E and
Supplementary Table 3).
We next looked at the molecular mechanisms involved in
response to BI119 in this animal model by measuring the
transcription of key inflammatory genes, including RORγt-
dependent targets in the intestinal mucosa. As expected, colitis
induced by CD4+CD45RBhigh T cells in immune-depleted
mice was associated with a significant increase in Th17 genes,
IFNG, IL10 as well as S100A8 (Figure 5) and S100A9 (data
not shown). In agreement with the clinical, macroscopic and
histologic protective effect of RORγt inhibition, oral BI119
treatment significantly reduced the expression of Th17-related
genes such as IL17A, IL17F, and IL22, as well as IFNG and
calprotectin (Figure 5). Remarkably, BI119 despite controlling
all the other inflammation-related genes, did not significantly
reduce transcription of IL10 in the colon. Besides the influence on
IL10, these in vivo experiments show a clear effect of oral BI119
administration in preventing T-cell driven murine experimental
colitis.
DISCUSSION
We report here a novel small-molecule orally active inhibitor
of RORγt as a potential strategy to treat CD. RORγt inhibition
resulting from oral administration of VTP-43742, a small
molecule antagonist that is known to be well tolerated and safe in
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FIGURE 4 | Impact of BI119 on T-cell-transfer colitic mice. (A) Body weight loss and colon tissue inflammation were reduced with BI119 treatment. (B) Fecal and
systemic biomarkers were inhibited in BI119-treated colitic mice. Lipocalin was measured by ELISA on fecal supernatants. sCD14 was measured by ELISA on plasma
samples. (C) Mucosal thickness was reduced in BI-treated colitic mice while (D) the histopathological score of colonic samples showed a trend but was not
significantly decreased in BI119-treated colitic mice. (E) Hematoxylin and eosin stained histologic sections of the distal colon of different mice groups. Mean ± SEM.
ns > 0.05, *P ≤ 0.05, ***P < 0.0005, ****P < 0.0001 compared to CD45+RBhigh mice.
healthy volunteers (23) and that has shown a signal of efficacy in
a phase II study in patients with psoriasis (NCT02555709). In the
context of IBD, evidence strongly supports the up-regulation and
involvement of the IL-23/Th17 pathway in disease pathogenesis.
However, results from clinical trials have shown that while
blocking the IL-23 p19 subunit can be beneficial in CD (7),
complete abrogation of IL-17 using mAbs has no benefit and
even leads to disease worsening in some patients. Despite this
undesirable effect, targeting of RORγt as an alternative approach
to modulate pathogenic Th17 responses, while preserving
protective ones, has been proposed. The key question remains
how interfering with RORγt-dependent pathways will not result
in the same undesirable effects observed upon IL-17 blockade in
CD patients.
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FIGURE 5 | Gene expression changes in T-cell-transfer colitic mice after BI119 treatment. IL17A, IL17F, IL22, IFNG and S100A8 expression was reduced in
BI119-treated colitic mice. IL10 expression was not altered using this treatment. Messenger RNA expression was assessed by real-time polymerase chain reaction.
Mean ± SEM. ns > 0.05, *P ≤ 0.05, **P < 0.005, ****P < 0.0001 compared to CD45+RBhigh mice.
Two main cell lineages require expression of RORγt for
their generation: Th17 (13), including a population of γδ
intraepithelial lymphocytes (24), and the ILC3 subset comprising
lymphoid tissue inducer (LTi)-derived cells (25) and natural
cytotoxic receptor NKp46-expressing ILC3s. RORγt+ cells drive
responses to extracellular bacteria and fungi by secreting several
cytokines (IL-17A, IL-17F, IL-22, and IL-26) that promote
neutrophil recruitment and epithelial microbial function (26).
Remarkably, these cells are particularly abundant in the intestinal
mucosa (27, 28) and have been described as being deregulated in
intestinal inflammation (1–4, 29–31).
Both Th17 and ILC3s are characterized by their production
of IL-17 and IL-22. Nonetheless, the requirement for RORγt
beyond lineage determination appears to differ among these
cell subsets, an important consideration when targeting RORγt
with agonists or antagonists (16, 17). Data in mice models
strongly suggests that while RORγt is necessary for lineage
development of all RORγt-expressing cell populations, its
expression acts predominantly to control IL-17 responses in
the CD4+ compartment, while the ability to produce the Th17
signature by ILC3 occurs independently of RORγt function
(19). This observation is further supported in human pediatric
CD-isolated lamina propria T and ILC3s cells where GSK805
(an orally-available inhibitor of RORγt) inhibited IL17 and
IL22 only on T cells but not on the lineage− CD127+ lamina
propria compartment (19). Therefore, while it is clear that ILC3s
depend on RORγt for their development, it remains to be
determined whether the nuclear receptor is also required for their
maintenance and function.
All this evidence suggests that transient inhibition of RORγt
activity effectively impacts T-cell-dependent Th17 responses in
disease-relevant scenarios. In agreement with that, our results
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show that the effector Th17 function of CD peripheral blood
bacterial (YidX and FrvX) responding cells can be significantly
modulated by RORγt inhibition. Furthermore, we provide
evidence that RORγt antagonism has a more profound effect
on the transcriptional regulation of ileal CD compared to
colonic inflammation. Given that Th17 are more predominant
in the small intestine (32), where they are driven by specific
microbial communities (33), it makes sense that the effects of
RORγt would be more profound in this particular intestinal
location. Finally, we show that RORγt inhibition significantly
ameliorates T-cell-dependent intestinal inflammation in the
CD4+CD45RBhigh T-cell transfer experimental model, which
supports the benefit of modulating Th17 responses in vivo to
control intestinal inflammation. Other experiments conducted
in this model demonstrated a more aggressive disease when
transferred CD4+CD45RBhigh T cells came from IL17A−/−
or IL17RA−/− donor mice (34). In contrast, Leppkes et al.
(35) and Krausgruber et al. (36) convincingly showed that
adoptive transfer of Rorc−/− CD4+ T cells into SCID recipients
failed to induce colitis and this correlated with reduced IL-
17A.
We should point out that at the doses used, BI119 treatment
did not result in complete abrogation of IL-17 secretion by
microbial-specific PBMCs, which would be a key difference with
the effects exerted by a mAb used at saturating doses. This could
represent a safety advantage in clinical use as it could potentially
maintain responses to pathogenic bacteria and fungi.
Moreover, while BI119 significantly decreased production of
IL-22 by PBMCs from CD disease patients, it did not regulate
transcription of this cytokine in actively inflamed colonic or ileal
biopsies. Besides antigen specific Th17 cells, IL-22 production
is characteristic of ILC3s (37), a cellular type most abundant
in the intestine and one that is significantly and selectively
increased in CD compared with healthy donors or ulcerative
colitis (UC) patients (31). These cells have been proposed to
have a protective role in mucosal sites through their ability
to produce IL-22, thereby inducing production of IL-10 by
epithelial cells. IL-22 also protects epithelial cells from apoptosis
through the activation of the transcription factor STAT3 (38,
39) and has regenerative properties on the epithelial stem cell
compartment (39). Overall, preserving IL-22 production in the
context of intestinal inflammation and homeostasis, despite
RORγt inhibition, may offer an advantage. However, we should
point out that the expression of IL22 is known to be upregulated
in the inflamed mucosa, both in CD and in experimental
models of colitis (40). Indeed, mucosal healing leads to the
control of IL22 expression in colitic mice receiving BI119.
This is not surprising, as one could expect that by protecting
mice from developing colitis, BI119 would be acting not only
against direct targets of RORγt (such as IL17A), but also on the
expression of indirect targets (IFNG or S100A8) associated with
the inflammatory response in colitis.
Besides the effects of BI119 on the signature of cytokine
production by Th17 cells, we demonstrate that RORγt inhibition
significantly downregulates transcription of the IL23R gene in
response to microbial stimuli in peripheral blood and in the ileal
mucosa of patients with CD, suggesting that one outcome of
this pharmacological intervention is regulation of the response
to IL-23 (a proven mediator and amplifier of disease in CD) (7).
An additional observed benefit of RORγt inhibition over IL-
17 blockade is the potential activation of the Foxp3-dependent
program upon RORγt antagonism. It is well known that the
Th17 and the Treg differentiation programs compete with
each other (41, 42). Indeed, RORγt physically associates with
Foxp3 to antagonize each other’s functions (15). We show
here that BI119 specifically represses the Th17 signature while
preserving the Th1 and Th2 pathways in PBMC cultures from
CD patients stimulated with microbial proteins; in contrast, both
FOXP3 transcription and IL-10 production were upregulated in
bacterial (YidX and FrvX) stimulated cultures. This observation
is consistent with work from the Kuchroo’s lab using murine
Th17 cells differentiated in vitro (15). While neither our
results nor previous studies (15) confirm the regulatory nature
of the emerging T cells exposed to the RORγt antagonist,
this observation suggests a potential added benefit of RORγt
antagonism over IL-17 blockade. The possibility that RORγt
antagonism could lead to a switch in the antigen-specific
responses toward a tolerogenic phenotype in CD patients is
highly intriguing and attractive; however, this remains only
a hypothesis that would need in-depth in vivo validation.
In agreement with this finding, mice receiving colitogenic
CD4+CD45RBhi T cells and the RORγt antagonist maintained
higher IL10 transcripts levels in tissue compared to non-colitic
controls. While further studies are needed to understand the
cellular source and mechanisms that result in this increased
IL10 expression in the non-inflamed colon, these results further
strengthen our hypothesis that by interfering with RORγt we
can promote regulatory functions. Overall, based on ours and
previous results, we propose that RORγt inhibition can effectively
modulate pathogenic CD-associated Th17 responses in periphery
and mucosa while sparing innate sources of IL-17 and IL-22 at
mucosal sites. This strategy would differ from blockingmAbs that
non-selectively and completely block IL-17, which is required
for control of extracellular bacteria and fungi. Furthermore, an
intriguing possibility is that antagonizing RORγt, as opposed to
IL-17 blockade, may lead to a transition of RORγt expressing cells
into regulatory T cells, thereby resulting in a decreased sensitivity
to IL-23 due to the downregulation of its receptor, a hypothesis
that would need further exploration.
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